With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio

Carly Helfand

 has been laboring to fill the void left by declining sales of aged pulmonary arterial hypertension (PAH) med Tracleer. And now, it has another tool to work with.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS